thiotepa has been researched along with Local Neoplasm Recurrence in 256 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine: (1) the maximum tolerable dose (MTD) of thiotepa (TT) that can be administered with etoposide without stem cell support; (2) whether this regimen is active against recurrent malignant gliomas." | 9.08 | Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study. ( Balmaceda, C; Fetell, MR; Hesdorffer, C, 1997) |
| "Twenty patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of procarbazine, thiotepa and vincristine (P." | 9.07 | Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. ( Ameri, A; Chen, QM; Delattre, JY; Poisson, M, 1993) |
| "To determine the role, if any, of one and five installations of intravesical thiotepa in the treatment of newly diagnosed superficial bladder cancer." | 9.07 | The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working P ( , 1994) |
| "This report presents the second interim analysis of data from a randomized prospective trial that compares the prophylactic effect of 15 intravesical instillations of 50 mg Doxorubicin (ADM), 50 mg of Thiotepa (TTPA), or 150 mg of Bacillus Calmette-Guérin (BCG) against recurrence and progression of superficial transitional cell bladder cancer." | 9.06 | Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. ( Cárcamo, P; Fiter, L; García Matres, MJ; Jimenez León, J; Martinez-Pineiro, JA; Martinez-Pineiro, L; Mosteiro, JA; Navarro, J, 1989) |
| "The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa." | 9.05 | Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. ( Barton, B; Hazra, TA; Heney, NM; Kluskens, L; Koontz, WW; Soloway, MS; Trump, DL, 1985) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 9.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "The influence of the instillation of thiotepa or doxorubicin hydrochloride into the bladder at the end of transurethral surgical treatment on the recurrence of bladder cancer was evaluated." | 9.05 | Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. ( Leary, FJ; Myers, RP; Taylor, WF; Utz, DC; Zincke, H, 1983) |
| "This report describes and presents some preliminary results from a prospective clinical investigation to determine the ablative effect of thiotepa (N,N',N''-triethylene phosphoramide) on superficial low-stage bladder cancer and the effectiveness of this agent in the prevention of recurrent or new tumors." | 9.04 | The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A. ( , 1977) |
| "Thiotepa-based conditioning followed by HSCT may be effective in most CNS lymphoma patients, with a manageable toxicity profile." | 8.90 | Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. ( Bredeson, C; Fergusson, D; Kokolo, MB; O'Neill, J; Stewart, D; Tay, J; Tinmouth, AT, 2014) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 7.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| "The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)." | 7.77 | Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011) |
| "Twenty-one percent of responding metastatic breast cancer patients remain progression-free a median 50 months following one intensification cycle of cyclophosphamide (6,000 mg/m2), thiotepa (500 mg/ m2), and carboplatin (800 mg/m2) (CTCb) with autologous bone marrow transplantation (ABMT)." | 7.69 | Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. ( Antman, K; Ayash, LJ; Elias, A; Frei, E; Ibrahim, J; Lynch, C; Reich, E; Richardson, P; Schnipper, L; Schwartz, G; Teicher, BA; Warren, D; Wheeler, C, 1996) |
| "To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)." | 7.68 | A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990) |
| "One hundred patients suffering from advanced breast cancers and resisting to one (15) or several (85) drugs previously administered have been treated by an association of mitomycin C, thiotepa and vindesine, given every 3 weeks." | 7.66 | [Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)]. ( Brunet, R; Bui, BN; Chauvergne, J; Durand, M; Hoerni, B; Mauriac, L, 1981) |
| "Recurrent medulloblastoma is highly lethal in previously irradiated patients." | 6.75 | High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. ( Dunkel, IJ; Finlay, JL; Gardner, SL; Garvin, JH; Goldman, S; Shi, W, 2010) |
| " Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions." | 6.67 | Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. ( Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992) |
| "Paclitaxel has minimal penetration of the blood-brain barrier and central nervous system side effects are rare." | 5.35 | Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. ( Fangusaro, J; Finlay, J; Rook, J; Rosser, T, 2008) |
| "Medulloblastoma is a highly lethal disease when it recurs." | 5.30 | High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. ( Allen, JC; Bostrom, BC; Boyett, JM; Dunkel, IJ; Finlay, JL; Gardner, SL; Garvin, JH; Goldman, S; Li, H; Rosenblum, M; Sender, LS; Yates, A, 1998) |
| " These patients with progressive bladder carcinoma appeared to be unaffected by intravesical thiotepa in the dosage used." | 5.27 | Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study. ( Fosså, SD; Miller, A; Stenwig, AE, 1983) |
| "We randomly assigned 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation." | 5.10 | Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. ( Fetting, J; Gradishar, WJ; Gray, R; Lazarus, HM; LeMaistre, CF; Osborne, CK; Paietta, E; Pisansky, TM; Robert, NJ; Tallman, MS; Vaughan, WP, 2003) |
| "To determine: (1) the maximum tolerable dose (MTD) of thiotepa (TT) that can be administered with etoposide without stem cell support; (2) whether this regimen is active against recurrent malignant gliomas." | 5.08 | Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study. ( Balmaceda, C; Fetell, MR; Hesdorffer, C, 1997) |
| " Conventional phase II clinical trials conducted in patients with recurrent or progressive brainstem gliomas using single chemotherapy agents such as cyclophosphamide, carboplatin, cisplatin, etoposide and thiotepa or combinations of chemotherapy agents have produced low response rates in the range of 15-20%." | 5.08 | Contemporary chemotherapy issues for children with brainstem gliomas. ( Allen, JC; Siffert, J, 1996) |
| "ThioTEPA is given intravesically in a variety of schedules to treat superficial bladder cancer." | 5.08 | ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. ( Bibby, MC; Harland, S; Loadman, PM; Masters, JR; McDermott, BJ, 1996) |
| "By conventional Phase II criteria, thiotepa appears to have activity in medulloblastoma." | 5.07 | A phase II evaluation of thiotepa in pediatric central nervous system malignancies. ( Allen, JC; Balis, FM; Gillespie, A; Heideman, RL; Horowitz, ME; Kovnar, EH; Lange, B; Packer, RJ; Reaman, GH; Steinberg, SM, 1993) |
| "To determine the role, if any, of one and five installations of intravesical thiotepa in the treatment of newly diagnosed superficial bladder cancer." | 5.07 | The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working P ( , 1994) |
| "Twenty patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of procarbazine, thiotepa and vincristine (P." | 5.07 | Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. ( Ameri, A; Chen, QM; Delattre, JY; Poisson, M, 1993) |
| "This report presents the second interim analysis of data from a randomized prospective trial that compares the prophylactic effect of 15 intravesical instillations of 50 mg Doxorubicin (ADM), 50 mg of Thiotepa (TTPA), or 150 mg of Bacillus Calmette-Guérin (BCG) against recurrence and progression of superficial transitional cell bladder cancer." | 5.06 | Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. ( Cárcamo, P; Fiter, L; García Matres, MJ; Jimenez León, J; Martinez-Pineiro, JA; Martinez-Pineiro, L; Mosteiro, JA; Navarro, J, 1989) |
| "The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa." | 5.05 | Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. ( Barton, B; Hazra, TA; Heney, NM; Kluskens, L; Koontz, WW; Soloway, MS; Trump, DL, 1985) |
| "The influence of the instillation of thiotepa or doxorubicin hydrochloride into the bladder at the end of transurethral surgical treatment on the recurrence of bladder cancer was evaluated." | 5.05 | Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. ( Leary, FJ; Myers, RP; Taylor, WF; Utz, DC; Zincke, H, 1983) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 5.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "This paper reports the preliminary results of an ongoing clinical trial in patients with category T1 bladder cancer who are randomized after transurethral resection to receive either thiotepa, VM-26, or no treatment." | 5.04 | Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study. ( De Pauw, M; Denis, L; Lachand, A; Pavone-Macaluso, M; Robinson, M; Schulman, C; Smith, P; Staquet, M; Sylvester, R, 1978) |
| "This report describes and presents some preliminary results from a prospective clinical investigation to determine the ablative effect of thiotepa (N,N',N''-triethylene phosphoramide) on superficial low-stage bladder cancer and the effectiveness of this agent in the prevention of recurrent or new tumors." | 5.04 | The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A. ( , 1977) |
| "Thiotepa-based conditioning followed by HSCT may be effective in most CNS lymphoma patients, with a manageable toxicity profile." | 4.90 | Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. ( Bredeson, C; Fergusson, D; Kokolo, MB; O'Neill, J; Stewart, D; Tay, J; Tinmouth, AT, 2014) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 3.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| " The authors report long-term survival of a 1-year-old patient with recurrent CPC and Li-Fraumeni syndrome with surgical resection and high-dose chemotherapy (HDC) consisting of single cycle of Busulfan and Thiotepa followed by autologous stem cell rescue without the use of radiation therapy." | 3.79 | Successful treatment of a recurrent choroid plexus carcinoma with surgery followed by high-dose chemotherapy and stem cell rescue. ( Bartels, U; Bouffet, E; Huang, A; Mosleh, O; Schechter, T; Tabori, U, 2013) |
| "The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)." | 3.77 | Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011) |
| "Twenty-seven children and adolescents with malignant astrocytomas [17 glioblastoma multiforme and 10 anaplastic astrocytoma (AA)] following initial tumor progression, received myeloablative chemotherapy followed by autologous marrow rescue with one of three thiotepa and etoposide-based chemotherapy regimens, administered alone (n = 11) or combined with carmustine (n = 5) or carboplatin (n = 11)." | 3.74 | Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. ( Boyett, JM; Dhall, G; Dunkel, IJ; Finlay, JL; Gardner, SL; Goldman, S; Packer, RJ; Pollack, IF; Rosenblum, MK; Stanley, P; Wallace, D; Yates, AJ; Zimmerman, RA, 2008) |
| " We report our experience with a 19-year-old girl with glioblastoma multiforme (GBM) of the deep temporal region recurring 6 months after completing an intensive treatment that included preradiation chemotherapy (chemotherapy as a preradiation "sandwich" phase) with a myeloablative course of thiotepa, tumor bed radiotherapy and postradiation maintenance chemotherapy." | 3.73 | A case of relapsing glioblastoma multiforme responding to vinorelbine. ( Biassoni, V; Casanova, M; Gandola, L; Massimino, M; Spreafico, F, 2006) |
| "Following local treatment and doxorubicin-containing standard chemotherapy, 42 patients with surgical Stage II or IIIA breast cancer containing ten or more involved axillary nodes and 13 patients with Stage IIIB disease were treated with high-dose chemotherapy (TMJ) consisting of thiotepa (750 mg/m2), mitoxantrone (40 mg/m2), and carboplatin (1000 mg/m2), with autologous bone marrow (ABM) and peripheral stem cell (PSC) transplant, followed by irradiation and/or hormone therapy." | 3.69 | TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer. ( Ahmed, T; Beer, M; Cook, P; Feldman, EJ; Lake, DE; Mittelman, A; Puccio, C; Razis, ED; Samonis, G, 1994) |
| "Twenty-one percent of responding metastatic breast cancer patients remain progression-free a median 50 months following one intensification cycle of cyclophosphamide (6,000 mg/m2), thiotepa (500 mg/ m2), and carboplatin (800 mg/m2) (CTCb) with autologous bone marrow transplantation (ABMT)." | 3.69 | Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. ( Antman, K; Ayash, LJ; Elias, A; Frei, E; Ibrahim, J; Lynch, C; Reich, E; Richardson, P; Schnipper, L; Schwartz, G; Teicher, BA; Warren, D; Wheeler, C, 1996) |
| "Fifty-three metastatic breast cancer patients were treated with a four-drug program of high-dose chemotherapy including cyclophosphamide (6 g/m2), thiotepa (500 mg/m2), carboplatin (800-1,600 mg/m2) and mitoxantrone (20-60 mg/m2) with autologous peripheral blood progenitor cell support followed by filgrastim." | 3.69 | [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer]. ( Alonso, JL; Ayala, F; Casado, A; Díaz-Rubio, E; Llorente, L; López Martín, JA; Martín, M; Nieto, Y; Pérez Calvo, J; Pérez López, C; Rodríguez Lescure, A; Villegas, A, 1997) |
| "To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)." | 3.68 | A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990) |
| "One hundred patients suffering from advanced breast cancers and resisting to one (15) or several (85) drugs previously administered have been treated by an association of mitomycin C, thiotepa and vindesine, given every 3 weeks." | 3.66 | [Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)]. ( Brunet, R; Bui, BN; Chauvergne, J; Durand, M; Hoerni, B; Mauriac, L, 1981) |
| "A course of combined therapy (adriablastin, cyclophosphan, vincristine and, in some cases, 5-fluorouracil) was given to 50 breast cancer patients with metastases of different localization." | 3.66 | [Combination chemotherapy including anablastine in disseminated breast cancer]. ( Ass, NIa; Dement'eva, IP; Lipovich, MM, 1981) |
| "Recurrent medulloblastoma is highly lethal in previously irradiated patients." | 2.75 | High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. ( Dunkel, IJ; Finlay, JL; Gardner, SL; Garvin, JH; Goldman, S; Shi, W, 2010) |
| " The tumours with a TOP2A amplification contributed hardly to this difference, suggesting that TOP2A amplification is not the cause of the steep dose-response curve for anthracyclines in breast cancer." | 2.72 | Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. ( Bontenbal, M; de Vries, EG; Hannemann, J; Hupperets, P; Kristel, P; Nooij, MA; Rodenhuis, S; Smit, WM; van de Vijver, MJ; van der Wall, E; van Hoesel, QG; van Tinteren, H; Voest, EE, 2006) |
| "Twenty patients with recurrent brain tumors aged 0." | 2.69 | Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. ( Boyett, JM; Dunkel, IJ; Finlay, JL; Gardner, S; Garvin, JH; Goldman, S; Gollamudi, S; Guruangan, S; Merchant, TE; Rosenblum, M, 1998) |
| "Patients with advanced epithelial ovarian cancer treated with salvage therapy using new combinations of systemic chemotherapy, radiation therapy, and systemic immunotherapy have had limited success." | 2.69 | A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study. ( Alvarez, RD; Berek, JS; Blessing, JA; DiSaia, PJ; Feun, LG; Major, FJ, 1998) |
| "Eleven patients with germ cell cancer relapsing from a complete remission and 7 patients with refractory germ cell cancer and/or an unresectable partial remission received salvage chemotherapy with one to two courses of carboplatin (800 mg/m2) and etoposide (500 mg/m2 on days 1, 3, and 5), followed by either one or two courses of carboplatin (1600 mg/m2), cyclophosphamide (6 g/m2), and thiotepa (480 mg/m2) divided over 4 days with autologous bone marrow transplantation and/or peripheral stem cell support." | 2.68 | Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. ( Richel, DJ; Rodenhuis, S; Schornagel, JH; ten Bokkel Huinink, WW; van der Wall, E; Vlasveld, LT, 1995) |
| "Women with metastatic breast cancer who had measurable disease, required laboratory tests, had received no prior chemotherapy for metastases, had a Cancer and Leukemia Group B (CALGB) performance status < or = 2, and provided informed consent were eligible." | 2.68 | Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. ( Abrams, J; Aisner, J; Budman, D; Cirrincione, C; Citron, M; Holland, J; Muss, H; Panasci, L; Perloff, M; Perry, M, 1995) |
| " Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions." | 2.67 | Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. ( Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992) |
| "Fifty-eight patients with disseminated breast cancer were randomly divided into 2 study groups." | 2.66 | [Evaluation of regimens for the simultaneous and sequential administration of cytostatics in the combined chemotherapy of disseminated forms of breast cancer]. ( Borisov, AI; Korman, DB; Maslova, IA; Pines, EV, 1985) |
| "Superficial bladder cancer can be treated surgically, but patients are at high risk for recurrence." | 2.43 | Bladder cancer: current optimal intravesical treatment. ( Hale, K; Lamm, DL; McGee, WR, 2005) |
| "The management of superficial bladder cancer has advanced significantly in recent years." | 2.39 | BCG in perspective: advances in the treatment of superficial bladder cancer. ( Lamm, DL, 1995) |
| "7." | 2.38 | Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. ( Jordan, AM; Murphy, WM; Soloway, MS, 1989) |
| "Management of the superficial bladder cancer patient consists of two complementary but separate therapeutic goals: treatment of the existing tumor(s) and prevention of tumor recurrence." | 2.37 | The biology and treatment of superficial bladder cancer. ( Lum, BL; Torti, FM, 1984) |
| "Most patients with bladder cancer initially present with localized, potentially curable tumours." | 2.36 | Treatment of superficial bladder cancer. ( Morales, A, 1980) |
| "All patients had high-risk hematologic malignancies, were younger than 20 years, and were in complete cytological remission at the time of allo-HSCT." | 1.91 | Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. ( Andersson, BS; Anurathapan, U; Hongeng, S; Pakakasama, S; Pongpitcha, P; Sirachainan, N; Songdej, D; Tannumsaeung, S, 2023) |
| "Eleven patients with non-germinomatous germ cell tumors and nine patients with germinomas were enrolled." | 1.39 | Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study. ( Baek, HJ; Han, JW; Im, HJ; Kang, HJ; Koh, KN; Lee, SH; Park, HJ; Park, KD; Sung, KW, 2013) |
| "Paclitaxel has minimal penetration of the blood-brain barrier and central nervous system side effects are rare." | 1.35 | Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. ( Fangusaro, J; Finlay, J; Rook, J; Rosser, T, 2008) |
| "A 56-year-old female with breast cancer after left partial mastectomy and subaxillary lymph node dissection was treated with adjuvant chemoradiotherapy." | 1.33 | [A case of recurrent breast cancer complicated with pericardial effusions and cardiac tamponade]. ( Ishiguro, A; Mitobe, S; Munakata, M; Okada, R; Sakata, Y; Shitara, K; Tomioka, R, 2006) |
| "Four cases had stage II or III breast cancer with over 10 positive axillary lymph nodes who had received radical surgical resection." | 1.30 | [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study]. ( Han, X; Pan, F; Shi, Y, 1999) |
| "Medulloblastoma is a highly lethal disease when it recurs." | 1.30 | High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. ( Allen, JC; Bostrom, BC; Boyett, JM; Dunkel, IJ; Finlay, JL; Gardner, SL; Garvin, JH; Goldman, S; Li, H; Rosenblum, M; Sender, LS; Yates, A, 1998) |
| "Stage II patients with breast carcinoma who had undergone lumpectomy." | 1.28 | Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial. ( Allen, S; Bosworth, H; Budman, D; Lehrman, D; Lichtman, SM; Schulman, P; Vinciguerra, V; Weiselberg, L; Weiss, R, 1991) |
| "One hundred fifty-five patients with urinary bladder cancer who were not suitable for radical surgery were treated with full-course radiotherapy, 6600 cGy in 9 weeks, split-course." | 1.28 | Recurrence and treatment of urinary bladder cancer after failure in radiotherapy. ( Salminen, E, 1990) |
| "Superficial bladder cancer has a good prognosis compared with invasive bladder cancer." | 1.28 | [Superficial bladder cancer: prophylaxis of recurrence and progression]. ( Akaza, H; Koiso, K; Miyanaga, N, 1991) |
| " These patients with progressive bladder carcinoma appeared to be unaffected by intravesical thiotepa in the dosage used." | 1.27 | Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study. ( Fosså, SD; Miller, A; Stenwig, AE, 1983) |
| "The incidence of bladder cancer is slowly rising, which may be due in part to the increasing use of chemicals in every phase of our modern society." | 1.27 | Bladder cancer. Management of an increasingly common tumor. ( Soloway, MS, 1983) |
| "Thiotepa has been used clinically for greater than 30 years but its pharmacokinetics remain poorly defined." | 1.27 | Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. ( Aisner, J; Cohen, BE; Egorin, MJ; Gutierrez, PL; Kohlhepp, EA, 1986) |
| "Recurrent bladder tumors developed subsequently in 80 per cent of the patients in group 1, 42." | 1.27 | A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors. ( Lemos, GC; Rodrigues Netto Júnior, N, 1983) |
| "Out of 3718 breast cancer patients treated at Petrov Research Institute of Oncology 262 patients [7%] proved to have minimal (less than 1 cm in diameter) form of breast cancer." | 1.27 | Minimal breast cancer. Clinical characteristics and treatment results. ( Orlov, AA; Pavlov, KA; Semiglazov, VF, 1983) |
| "A case of distant metastases of a giant cell tumor of the radius is presented." | 1.27 | Extensive distal subcutaneous metastases of a "benign" giant cell tumor of the radius. ( Muirragui, A; Serra, JM; Tadjalli, H, 1985) |
| "Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin." | 1.26 | Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. ( Bruce, AW; Eidinger, D; Morales, A, 1976) |
| " Continuing maintenance therapy was required in the majority but, with the passage of time, the dosage could be progressively reduced, suggesting a cumulative effect of treatment." | 1.26 | Early multiple-dose adjuvant thiotepa in the control of multiple and rapid T1 tumour neogenesis. ( Blandy, JP; England, HR; Flynn, JT; Paris, AM, 1981) |
| "Recurrent transitional cell carcinoma was treated with prophylactic intravesical thio-tepa in 22 cases." | 1.26 | Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder. ( Gavrell, GJ; Leblanc, GA; Lewis, RW; Meehan, WL, 1978) |
| "Serious leukopenia was found in 2 of the 48 patients receiving the combined instillation therapy but we concluded that this was not attributable to the use of urokinase." | 1.25 | The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report. ( Hisazumi, H; Misaki, T; Miyazaki, K; Naito, K; Uchibayashi, T, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 148 (57.81) | 18.7374 |
| 1990's | 47 (18.36) | 18.2507 |
| 2000's | 32 (12.50) | 29.6817 |
| 2010's | 18 (7.03) | 24.3611 |
| 2020's | 11 (4.30) | 2.80 |
| Authors | Studies |
|---|---|
| Schenone, L | 1 |
| Houillier, C | 1 |
| Tanguy, ML | 1 |
| Choquet, S | 3 |
| Agbetiafa, K | 1 |
| Ghesquières, H | 1 |
| Damaj, G | 1 |
| Schmitt, A | 1 |
| Bouabdallah, K | 1 |
| Ahle, G | 1 |
| Gressin, R | 1 |
| Cornillon, J | 1 |
| Houot, R | 1 |
| Marolleau, JP | 1 |
| Fornecker, LM | 1 |
| Chinot, O | 1 |
| Peyrade, F | 1 |
| Bouabdallah, R | 1 |
| Moluçon-Chabrot, C | 1 |
| Gyan, E | 1 |
| Chauchet, A | 1 |
| Casasnovas, O | 2 |
| Oberic, L | 1 |
| Delwail, V | 1 |
| Abraham, J | 1 |
| Roland, V | 1 |
| Waultier-Rascalou, A | 1 |
| Willems, L | 1 |
| Morschhauser, F | 1 |
| Fabbro, M | 1 |
| Ursu, R | 1 |
| Thieblemont, C | 1 |
| Jardin, F | 1 |
| Tempescul, A | 1 |
| Malaise, D | 1 |
| Touitou, V | 1 |
| Nichelli, L | 1 |
| Le Garff-Tavernier, M | 1 |
| Plessier, A | 1 |
| Bourget, P | 1 |
| Bonmati, C | 1 |
| Wantz-Mézières, S | 1 |
| Giordan, Q | 1 |
| Dorvaux, V | 1 |
| Charron, C | 1 |
| Jabeur, W | 1 |
| Hoang-Xuan, K | 4 |
| Taillandier, L | 2 |
| Soussain, C | 4 |
| Finke, J | 2 |
| Schmoor, C | 1 |
| Stelljes, M | 1 |
| Burchert, A | 1 |
| Dreger, P | 1 |
| Hegenbart, U | 1 |
| Wagner-Drouet, EM | 1 |
| Bornhäuser, M | 1 |
| Sohlbach, K | 1 |
| Schub, N | 1 |
| Reicherts, C | 1 |
| Kobbe, G | 1 |
| Glass, B | 1 |
| Bertz, H | 1 |
| Grishina, O | 2 |
| Tannumsaeung, S | 3 |
| Anurathapan, U | 3 |
| Pakakasama, S | 3 |
| Pongpitcha, P | 3 |
| Songdej, D | 3 |
| Sirachainan, N | 3 |
| Andersson, BS | 3 |
| Hongeng, S | 3 |
| Othman, T | 1 |
| Quan, MA | 1 |
| Zhang, S | 1 |
| Gaut, D | 1 |
| Young, PA | 1 |
| Mahmood, O | 1 |
| Abdulhaq, H | 1 |
| Shieh, K | 1 |
| Reid, J | 1 |
| Brem, EA | 1 |
| Hariharan, N | 1 |
| Heyman, B | 1 |
| Tuscano, J | 1 |
| Arshad, S | 1 |
| Fang, X | 1 |
| Ahn, KW | 2 |
| Kaur, M | 1 |
| Scordo, M | 2 |
| Sauter, CS | 3 |
| Furqan, F | 1 |
| Awan, FT | 2 |
| Hamadani, M | 2 |
| Alderuccio, JP | 1 |
| Nayak, L | 1 |
| Cwynarski, K | 1 |
| Faraj, K | 1 |
| Chang, YH | 1 |
| Rose, KM | 1 |
| Habermann, EB | 1 |
| Etzioni, DA | 1 |
| Blodgett, G | 1 |
| Castle, EP | 1 |
| Humphreys, MR | 1 |
| Tyson Ii, MD | 1 |
| Peric, Z | 1 |
| Mohty, R | 1 |
| Bastos, J | 1 |
| Brissot, E | 1 |
| Battipaglia, G | 1 |
| Belhocine, R | 1 |
| Sestili, S | 1 |
| Giannotti, F | 1 |
| Vekhoff, A | 1 |
| Ledraa, T | 1 |
| Legrand, O | 1 |
| Lapusan, S | 1 |
| Isnard, F | 1 |
| Labopin, M | 1 |
| Bonnin, A | 1 |
| Mediavilla, C | 1 |
| Rubio, MT | 1 |
| Ruggeri, A | 1 |
| Duléry, R | 1 |
| Malard, F | 1 |
| Mohty, M | 1 |
| de Boo, L | 1 |
| Cimino-Mathews, A | 1 |
| Lubeck, Y | 1 |
| Daletzakis, A | 1 |
| Opdam, M | 1 |
| Sanders, J | 3 |
| Hooijberg, E | 1 |
| van Rossum, A | 1 |
| Loncova, Z | 1 |
| Rieder, D | 1 |
| Trajanoski, Z | 1 |
| Vollebergh, M | 1 |
| Sobral-Leite, M | 1 |
| van de Vijver, K | 1 |
| Broeks, A | 1 |
| van der Wiel, R | 1 |
| van Tinteren, H | 3 |
| Linn, S | 1 |
| Horlings, HM | 1 |
| Kok, M | 1 |
| Ma, Y | 1 |
| Lim, DH | 1 |
| Cho, H | 1 |
| Lee, JW | 2 |
| Sung, KW | 2 |
| Yoo, KH | 1 |
| Koo, HH | 1 |
| Shin, HJ | 1 |
| Suh, YL | 1 |
| Wang, TP | 1 |
| Chen, Y | 1 |
| Ahmed, S | 1 |
| Beitinjaneh, A | 1 |
| Chen, A | 1 |
| Chow, VA | 1 |
| Dholaria, B | 1 |
| Epperla, N | 1 |
| Farooq, U | 1 |
| Ghosh, N | 1 |
| Grover, N | 1 |
| Hamad, N | 1 |
| Hildebrandt, GC | 1 |
| Holmberg, L | 1 |
| Hong, S | 1 |
| Inwards, DJ | 1 |
| Jimenez-Jimenez, A | 1 |
| Karmali, R | 1 |
| Kenkre, VP | 1 |
| Khimani, F | 1 |
| Klyuchnikov, E | 1 |
| Krem, MM | 1 |
| Munshi, PN | 1 |
| Nieto, Y | 2 |
| Prestidge, T | 1 |
| Ramakrishnan Geethakumari, P | 1 |
| Rezvani, AR | 1 |
| Riedell, PA | 1 |
| Seo, S | 1 |
| Shah, NN | 1 |
| Solh, M | 1 |
| Yared, JA | 1 |
| Kharfan-Dabaja, MA | 1 |
| Herrera, A | 1 |
| Takahashi, M | 1 |
| Sumitani, R | 1 |
| Hori, T | 1 |
| Murai, J | 1 |
| Kawata, S | 1 |
| Oura, M | 1 |
| Sogabe, K | 1 |
| Harada, T | 1 |
| Fujii, S | 1 |
| Miki, H | 1 |
| Kagawa, K | 1 |
| Abe, M | 1 |
| Nakamura, S | 1 |
| Lafrenie, RM | 1 |
| Speigl, L | 1 |
| Buckner, CA | 1 |
| Pawelec, G | 1 |
| Conlon, MS | 1 |
| Shipp, C | 1 |
| Baek, HJ | 1 |
| Park, HJ | 1 |
| Lee, SH | 1 |
| Han, JW | 1 |
| Koh, KN | 1 |
| Im, HJ | 1 |
| Kang, HJ | 1 |
| Park, KD | 1 |
| Chen, F | 1 |
| Chen, K | 1 |
| Kokolo, MB | 1 |
| Fergusson, D | 1 |
| O'Neill, J | 1 |
| Tay, J | 1 |
| Tinmouth, AT | 1 |
| Stewart, D | 2 |
| Bredeson, C | 1 |
| Welch, MR | 1 |
| Matasar, MJ | 1 |
| Faivre, G | 1 |
| Weaver, SA | 1 |
| Moskowitz, CH | 1 |
| Omuro, AM | 1 |
| Sylvester, RJ | 1 |
| Oosterlinck, W | 2 |
| Holmang, S | 1 |
| Sydes, MR | 1 |
| Birtle, A | 1 |
| Gudjonsson, S | 1 |
| De Nunzio, C | 1 |
| Okamura, K | 1 |
| Kaasinen, E | 1 |
| Solsona, E | 1 |
| Ali-El-Dein, B | 1 |
| Tatar, CA | 1 |
| Inman, BA | 1 |
| N'Dow, J | 1 |
| Oddens, JR | 1 |
| Babjuk, M | 1 |
| Dardis, C | 1 |
| Milton, K | 1 |
| Ashby, L | 1 |
| Lee, MY | 1 |
| Kim, HS | 1 |
| Lee, JY | 1 |
| Lim, SH | 1 |
| Kang, ES | 1 |
| Ko, YH | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Schorb, E | 1 |
| Ferreri, AJ | 1 |
| Ihorst, G | 1 |
| Mikesch, K | 1 |
| Kasenda, B | 1 |
| Fritsch, K | 1 |
| Fricker, H | 1 |
| Burger, E | 1 |
| Valk, E | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Lu, DD | 1 |
| Boorjian, SA | 1 |
| Raman, JD | 1 |
| Finlay, JL | 7 |
| Dhall, G | 2 |
| Boyett, JM | 4 |
| Dunkel, IJ | 7 |
| Gardner, SL | 3 |
| Goldman, S | 5 |
| Yates, AJ | 2 |
| Rosenblum, MK | 2 |
| Stanley, P | 2 |
| Zimmerman, RA | 2 |
| Wallace, D | 1 |
| Pollack, IF | 1 |
| Packer, RJ | 4 |
| Massimino, M | 2 |
| Gandola, L | 2 |
| Spreafico, F | 2 |
| Biassoni, V | 2 |
| Luksch, R | 1 |
| Collini, P | 1 |
| Solero, CN | 1 |
| Simonetti, F | 1 |
| Pignoli, E | 1 |
| Cefalo, G | 1 |
| Poggi, G | 1 |
| Modena, P | 1 |
| Mariani, L | 1 |
| Potepan, P | 1 |
| Podda, M | 1 |
| Casanova, M | 2 |
| Pecori, E | 1 |
| Acerno, S | 1 |
| Ferrari, A | 1 |
| Terenziani, M | 1 |
| Meazza, C | 1 |
| Polastri, D | 1 |
| Ravagnani, F | 1 |
| Fossati-Bellani, F | 1 |
| Grodman, H | 1 |
| Wolfe, L | 1 |
| Kretschmar, C | 1 |
| Butturini, AM | 1 |
| Jacob, M | 1 |
| Aguajo, J | 1 |
| Vander-Walde, NA | 1 |
| Villablanca, J | 1 |
| Jubran, R | 1 |
| Erdreich-Epstein, A | 1 |
| Marachelian, A | 1 |
| Gilheeney, SW | 1 |
| Khakoo, Y | 1 |
| Souweidane, M | 1 |
| Wolden, S | 1 |
| Boulad, F | 1 |
| Garvin, JH | 3 |
| Shi, W | 1 |
| Daveau, C | 1 |
| Savignoni, A | 1 |
| Abrous-Anane, S | 1 |
| Pierga, JY | 1 |
| Reyal, F | 1 |
| Gautier, C | 1 |
| Kirova, YM | 1 |
| Dendale, R | 1 |
| Campana, F | 1 |
| Fourquet, A | 1 |
| Bollet, MA | 1 |
| del Rio, MS | 1 |
| Glaisner, S | 1 |
| Fourme, E | 2 |
| Janvier, M | 2 |
| Miura, Y | 1 |
| Toyooka, N | 1 |
| Iwai, F | 1 |
| Matsui, Y | 1 |
| Hirai, M | 1 |
| Kaneko, H | 1 |
| Watanabe, M | 1 |
| Tsudo, M | 1 |
| Fay, MP | 1 |
| Shih, JH | 1 |
| Mosleh, O | 1 |
| Tabori, U | 1 |
| Bartels, U | 1 |
| Huang, A | 1 |
| Schechter, T | 1 |
| Bouffet, E | 2 |
| Rodenhuis, S | 3 |
| Bontenbal, M | 2 |
| Beex, LV | 1 |
| Wagstaff, J | 1 |
| Richel, DJ | 2 |
| Nooij, MA | 2 |
| Voest, EE | 2 |
| Hupperets, P | 2 |
| Peterse, HL | 1 |
| TenVergert, EM | 1 |
| de Vries, EG | 2 |
| Tallman, MS | 1 |
| Gray, R | 2 |
| Robert, NJ | 1 |
| LeMaistre, CF | 1 |
| Osborne, CK | 1 |
| Vaughan, WP | 1 |
| Gradishar, WJ | 1 |
| Pisansky, TM | 1 |
| Fetting, J | 1 |
| Paietta, E | 1 |
| Lazarus, HM | 1 |
| GRECO, T | 1 |
| HANKINS, GW | 1 |
| MCCARTEN, AB | 1 |
| IMANAGA, H | 1 |
| EDELSTYN, GA | 1 |
| COLE, WH | 1 |
| ROBERTS, SS | 1 |
| WEBB, RS | 1 |
| STREHL, FW | 1 |
| OATES, GD | 1 |
| Fagioli, F | 1 |
| Biasin, E | 1 |
| Mastrodicasa, L | 1 |
| Sandri, A | 1 |
| Ferrero, I | 1 |
| Berger, M | 1 |
| Vassallo, E | 1 |
| Madon, E | 1 |
| Modak, S | 2 |
| Gardner, S | 3 |
| Balmaceda, C | 3 |
| Miller, DC | 2 |
| Halpern, S | 1 |
| Campbell, AD | 1 |
| Cohn, SL | 1 |
| Reynolds, M | 1 |
| Seshadri, R | 1 |
| Morgan, E | 1 |
| Geissler, G | 1 |
| Rademaker, A | 1 |
| Marymount, M | 1 |
| Kalapurakal, J | 1 |
| Haut, PR | 1 |
| Duerst, R | 1 |
| Kletzel, M | 1 |
| Shim, BY | 1 |
| Lee, MA | 1 |
| Byun, JH | 1 |
| Roh, SY | 1 |
| Song, CW | 1 |
| Park, JN | 1 |
| Min, WS | 1 |
| Hong, YS | 1 |
| Kim, CC | 1 |
| Pérez-Martínez, A | 1 |
| Lassaletta, A | 1 |
| González-Vicent, M | 1 |
| Sevilla, J | 1 |
| Díaz, MA | 1 |
| Madero, L | 1 |
| Lamm, DL | 3 |
| McGee, WR | 1 |
| Hale, K | 1 |
| Kushner, BH | 1 |
| Kramer, K | 1 |
| Kernan, NA | 1 |
| Reich, LM | 1 |
| Danis, K | 1 |
| Cheung, NK | 1 |
| Stern, BV | 1 |
| Baehring, JM | 1 |
| Kleopa, KA | 1 |
| Hochberg, FH | 1 |
| Shitara, K | 1 |
| Munakata, M | 1 |
| Ishiguro, A | 1 |
| Okada, R | 1 |
| Tomioka, R | 1 |
| Mitobe, S | 1 |
| Sakata, Y | 1 |
| Zacharoulis, S | 1 |
| Levy, A | 1 |
| Chi, SN | 1 |
| Rosenblum, M | 3 |
| Dunkel, I | 1 |
| Diez, B | 1 |
| Sposto, R | 1 |
| Ji, L | 1 |
| Asgharzadeh, S | 1 |
| Hukin, J | 1 |
| Belasco, J | 1 |
| Dubowy, R | 1 |
| Kellie, S | 1 |
| Termuhlen, A | 1 |
| Finlay, J | 2 |
| Rook, J | 1 |
| Rosser, T | 1 |
| Fangusaro, J | 1 |
| Hannemann, J | 1 |
| Kristel, P | 1 |
| van Hoesel, QG | 1 |
| Smit, WM | 1 |
| van der Wall, E | 2 |
| van de Vijver, MJ | 1 |
| Ridola, V | 1 |
| Grill, J | 2 |
| Doz, F | 3 |
| Gentet, JC | 1 |
| Frappaz, D | 1 |
| Raquin, MA | 1 |
| Habrand, JL | 1 |
| Sainte-Rose, C | 2 |
| Valteau-Couanet, D | 2 |
| Kalifa, C | 3 |
| Izumi, K | 1 |
| Kanno, H | 1 |
| Umemoto, S | 1 |
| Hasumi, H | 1 |
| Osada, Y | 1 |
| Otai, J | 1 |
| Mikata, K | 1 |
| Tsuchiya, F | 1 |
| Nagashima, Y | 1 |
| Choi, LM | 1 |
| Rood, B | 1 |
| Kamani, N | 1 |
| La Fond, D | 1 |
| Santi, MR | 1 |
| Macdonald, TJ | 1 |
| Gill, P | 1 |
| Litzow, M | 1 |
| Buckner, J | 1 |
| Arndt, C | 1 |
| Moynihan, T | 1 |
| Christianson, T | 1 |
| Ansell, S | 1 |
| Galanis, E | 1 |
| Witz, F | 1 |
| Dupriez, B | 1 |
| Souleau, B | 1 |
| Taksin, AL | 1 |
| Gisselbrecht, C | 1 |
| Jaccard, A | 1 |
| Omuro, A | 1 |
| Sanson, M | 1 |
| Kolb, B | 1 |
| Zini, JM | 1 |
| Leblond, V | 2 |
| Semiglazov, VF | 2 |
| Pavlov, KA | 1 |
| Orlov, AA | 2 |
| Rodrigues Netto Júnior, N | 1 |
| Lemos, GC | 1 |
| Soloway, MS | 8 |
| Zincke, H | 2 |
| Utz, DC | 1 |
| Taylor, WF | 2 |
| Myers, RP | 1 |
| Leary, FJ | 1 |
| Cohen, CJ | 1 |
| Goldberg, JD | 1 |
| Holland, JF | 1 |
| Bruckner, HW | 1 |
| Deppe, G | 1 |
| Gusberg, SB | 1 |
| Wallach, RC | 1 |
| Kabakow, B | 1 |
| Rodin, J | 1 |
| Dalesio, O | 3 |
| Schulman, CC | 4 |
| Sylvester, R | 5 |
| De Pauw, M | 4 |
| Robinson, M | 3 |
| Denis, L | 4 |
| Smith, P | 3 |
| Viggiano, G | 3 |
| Toulouse, J | 1 |
| Bouffier, B | 1 |
| Etievent, JP | 1 |
| Bittard, M | 1 |
| Lum, BL | 2 |
| Fosså, SD | 2 |
| Miller, A | 1 |
| Stenwig, AE | 1 |
| Nissenkorn, I | 1 |
| Slutzker, D | 1 |
| Schujman, E | 1 |
| Servadio, C | 2 |
| Prout, GR | 4 |
| Koontz, WW | 4 |
| Coombs, LJ | 1 |
| Hawkins, IR | 1 |
| Friedell, GH | 2 |
| Pavone-Macaluso, M | 5 |
| Tripi, M | 1 |
| Ingargiola, GB | 1 |
| Green, DF | 1 |
| Robinson, MR | 1 |
| Glashan, R | 1 |
| Newling, D | 1 |
| Smith, PH | 1 |
| Wong, SH | 1 |
| Poon, GP | 1 |
| Dzhilavian, GA | 1 |
| Vinokurov, VL | 1 |
| Torti, FM | 1 |
| Powder, JR | 1 |
| Mosberg, WH | 1 |
| Pierpont, RZ | 1 |
| Tatoyan, KB | 1 |
| Young, JD | 1 |
| Martínez-Piñeiro, JA | 3 |
| Kopp, J | 1 |
| Akdaş, A | 1 |
| Kirkali, Z | 1 |
| Sengör, F | 1 |
| Ilker, Y | 1 |
| Taşar, C | 1 |
| Asahi, T | 1 |
| Matsumura, Y | 1 |
| Tanahashi, T | 1 |
| Yoshimoto, J | 1 |
| Kaneshige, T | 1 |
| Fujita, Y | 1 |
| Ohmori, H | 1 |
| Konnak, JW | 1 |
| Morales, A | 2 |
| Kovalenko, AV | 1 |
| Saito, K | 1 |
| Fukushima, S | 1 |
| Takahashi, Y | 1 |
| Takai, S | 1 |
| Smith, W | 1 |
| Frable, WJ | 1 |
| Minnis, JE | 1 |
| Sauvage, R | 1 |
| Sergel', OS | 1 |
| Kopeĭko, IP | 1 |
| Kachkov, AP | 1 |
| Ghosal, SK | 1 |
| Sen, DK | 1 |
| Dement'eva, IP | 1 |
| Ass, NIa | 1 |
| Lipovich, MM | 1 |
| Kulkarni, JN | 1 |
| Kamat, MR | 1 |
| Juvekar, RL | 1 |
| England, HR | 1 |
| Flynn, JT | 1 |
| Paris, AM | 1 |
| Blandy, JP | 1 |
| Chauvergne, J | 2 |
| Durand, M | 3 |
| Brunet, R | 1 |
| Bui, BN | 1 |
| Hoerni, B | 1 |
| Mauriac, L | 3 |
| Brosman, SA | 1 |
| Baumgartner, G | 1 |
| Ogawa, M | 1 |
| Mukaiyama, T | 1 |
| ten Bokkel Huinink, WW | 1 |
| Schornagel, JH | 1 |
| Vlasveld, LT | 1 |
| Seregard, S | 1 |
| Kock, E | 1 |
| af Trampe, E | 1 |
| Aisner, J | 2 |
| Cirrincione, C | 1 |
| Perloff, M | 1 |
| Perry, M | 1 |
| Budman, D | 2 |
| Abrams, J | 1 |
| Panasci, L | 1 |
| Muss, H | 1 |
| Citron, M | 1 |
| Holland, J | 1 |
| Krementz, ET | 1 |
| Carter, RD | 1 |
| Sutherland, CM | 1 |
| Muchmore, JH | 1 |
| Ryan, RF | 1 |
| Creech, O | 1 |
| Razis, ED | 1 |
| Samonis, G | 1 |
| Cook, P | 1 |
| Beer, M | 1 |
| Mittelman, A | 1 |
| Lake, DE | 1 |
| Feldman, EJ | 1 |
| Puccio, C | 1 |
| Ahmed, T | 1 |
| Mukamel, E | 1 |
| Ameri, A | 1 |
| Poisson, M | 1 |
| Chen, QM | 1 |
| Delattre, JY | 2 |
| Bretheau, D | 1 |
| Lechevallier, E | 1 |
| Jean, F | 1 |
| Rampal, M | 1 |
| Coulange, C | 1 |
| Albain, KS | 1 |
| Crowley, JJ | 1 |
| Hutchins, L | 1 |
| Gandara, D | 1 |
| O'Bryan, RM | 1 |
| Von Hoff, DD | 1 |
| Griffin, B | 1 |
| Livingston, RB | 1 |
| Tormey, DC | 2 |
| Falkson, HC | 1 |
| Gilchrist, K | 1 |
| Abeloff, MD | 1 |
| Falkson, G | 2 |
| Heideman, RL | 1 |
| Reaman, GH | 1 |
| Allen, JC | 3 |
| Lange, B | 1 |
| Horowitz, ME | 1 |
| Steinberg, SM | 1 |
| Gillespie, A | 1 |
| Kovnar, EH | 1 |
| Balis, FM | 1 |
| Masters, JR | 1 |
| McDermott, BJ | 1 |
| Harland, S | 1 |
| Bibby, MC | 1 |
| Loadman, PM | 1 |
| Wong, MC | 1 |
| Cairo, M | 1 |
| Garvin, J | 1 |
| August, C | 1 |
| Cohen, BH | 1 |
| Bostrom, B | 1 |
| Geyer, JR | 1 |
| Harris, RE | 1 |
| Siffert, J | 1 |
| Ayash, LJ | 1 |
| Elias, A | 1 |
| Schwartz, G | 1 |
| Wheeler, C | 1 |
| Ibrahim, J | 1 |
| Teicher, BA | 1 |
| Reich, E | 1 |
| Warren, D | 1 |
| Lynch, C | 1 |
| Richardson, P | 1 |
| Schnipper, L | 1 |
| Frei, E | 1 |
| Antman, K | 1 |
| Chamberlain, MC | 1 |
| Schoepfer, C | 1 |
| Couanet, D | 1 |
| Terrier-Lacombe, MJ | 1 |
| Hartmann, O | 2 |
| Ariyan, S | 1 |
| Poo, WJ | 1 |
| Bolognia, J | 1 |
| Fetell, MR | 1 |
| Hesdorffer, C | 1 |
| Dupuis-Girod, S | 1 |
| Benhamou, E | 1 |
| Mechinaud, F | 1 |
| Coze, C | 1 |
| Solano, C | 1 |
| Sola, C | 1 |
| Lluch, A | 1 |
| Hornedo, J | 1 |
| López, J | 1 |
| Cortés-Funes, H | 1 |
| García-Conde, J | 1 |
| Yates, A | 1 |
| Bostrom, BC | 1 |
| Sender, LS | 1 |
| Li, H | 1 |
| Martín, M | 1 |
| Casado, A | 1 |
| Llorente, L | 1 |
| López Martín, JA | 1 |
| Rodríguez Lescure, A | 1 |
| Ayala, F | 1 |
| Pérez Calvo, J | 1 |
| Alonso, JL | 1 |
| Pérez López, C | 1 |
| Villegas, A | 1 |
| Díaz-Rubio, E | 1 |
| Guruangan, S | 1 |
| Merchant, TE | 1 |
| Gollamudi, S | 1 |
| Feun, LG | 1 |
| Blessing, JA | 1 |
| Major, FJ | 1 |
| DiSaia, PJ | 1 |
| Alvarez, RD | 1 |
| Berek, JS | 1 |
| Papadopoulos, KP | 1 |
| Fetell, M | 1 |
| Kaufman, E | 1 |
| Vahdat, LT | 1 |
| Bruce, J | 1 |
| Sisti, M | 1 |
| Isaacson, S | 1 |
| De LaPaz, R | 1 |
| Savage, DG | 1 |
| Troxel, A | 1 |
| Antman, KH | 1 |
| Hesdorffer, CS | 1 |
| Hawkins, D | 1 |
| Barnett, T | 1 |
| Bensinger, W | 1 |
| Gooley, T | 1 |
| Suzan, F | 1 |
| Cassoux, N | 1 |
| Levy, V | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Cairncross, G | 1 |
| Swinnen, L | 1 |
| Bayer, R | 1 |
| Rosenfeld, S | 1 |
| Salzman, D | 1 |
| Paleologos, N | 1 |
| Kaminer, L | 1 |
| Forsyth, P | 1 |
| Peterson, K | 1 |
| Hu, W | 1 |
| Macdonald, D | 1 |
| Ramsay, D | 1 |
| Smith, A | 1 |
| Stemmer, SM | 1 |
| Pfeffer, MR | 1 |
| Rizel, S | 1 |
| Hardan, I | 1 |
| Goffman, J | 1 |
| Gezin, A | 1 |
| Neumann, A | 1 |
| Kitsios, P | 1 |
| Alezra, D | 1 |
| Brenner, HJ | 1 |
| Lindsey, JK | 1 |
| Shi, Y | 1 |
| Pan, F | 1 |
| Han, X | 1 |
| Yang, D | 1 |
| Li, S | 1 |
| Wang, H | 1 |
| Li, X | 1 |
| Liu, S | 1 |
| Han, W | 1 |
| Hao, J | 1 |
| Zhang, H | 1 |
| Fisher, PG | 1 |
| Kadan-Lottick, NS | 1 |
| Korones, DN | 1 |
| Heath, JA | 1 |
| Broxson, EH | 1 |
| Dole, MG | 1 |
| Filippa, DA | 1 |
| George, D | 1 |
| Lyden, D | 1 |
| Gavrell, GJ | 1 |
| Lewis, RW | 1 |
| Meehan, WL | 1 |
| Leblanc, GA | 1 |
| Schulman, C | 1 |
| Lachand, A | 1 |
| Staquet, M | 2 |
| Jacquillat, C | 1 |
| Banzet, P | 1 |
| Civatte, J | 1 |
| Puissant, A | 1 |
| Cottenot, F | 1 |
| Israel, L | 1 |
| Belaich, S | 1 |
| Chastang, C | 1 |
| Maral, J | 1 |
| Csellár, M | 1 |
| Csontai, A | 1 |
| Okajima, E | 3 |
| Motomiya, Y | 1 |
| Ishuin, M | 1 |
| Ikuma, S | 1 |
| Ohara, S | 2 |
| Fournier, R | 1 |
| Viville, C | 1 |
| Byar, D | 1 |
| Blackard, C | 1 |
| Boyd, PJ | 2 |
| Burnand, KG | 2 |
| Hisazumi, H | 1 |
| Uchibayashi, T | 1 |
| Naito, K | 1 |
| Misaki, T | 1 |
| Miyazaki, K | 1 |
| Cox, KR | 1 |
| Mayo, ME | 1 |
| Shuttleworth, KE | 1 |
| Lloyd-Davies, RW | 1 |
| Eidinger, D | 1 |
| Bruce, AW | 1 |
| Rozencweig, M | 1 |
| Kenis, Y | 1 |
| Topuzov, EE | 1 |
| Bavli, IaL | 1 |
| Ivanova, OA | 1 |
| Seleznev, IK | 1 |
| Golubeva, OM | 1 |
| Chepik, OF | 1 |
| Wang, SH | 1 |
| Hirao, Y | 2 |
| Ozono, S | 2 |
| Samma, S | 1 |
| Sasaki, K | 1 |
| Hiramatsu, T | 2 |
| Babaya, K | 1 |
| Watanabe, S | 2 |
| Maruyama, Y | 1 |
| Dilhuydy, JM | 2 |
| Bonichon, F | 1 |
| Bordalba Gómez, JR | 1 |
| Muñoz Segui, J | 1 |
| Aguilo, F | 1 |
| Gil Vernet, A | 1 |
| Vigues, F | 1 |
| Lopez Costea, MA | 1 |
| Serrallach, N | 1 |
| Bouffioux, C | 1 |
| Vergison, B | 1 |
| Keuppens, F | 1 |
| Cheuvart, B | 1 |
| Salminen, E | 1 |
| Miyanaga, N | 1 |
| Akaza, H | 1 |
| Koiso, K | 1 |
| Lichtman, SM | 1 |
| Bosworth, H | 1 |
| Allen, S | 1 |
| Schulman, P | 1 |
| Weiselberg, L | 1 |
| Weiss, R | 1 |
| Lehrman, D | 1 |
| Vinciguerra, V | 1 |
| Martelli, MF | 1 |
| Aversa, F | 1 |
| Avril, A | 1 |
| Jiménez León, J | 2 |
| Martínez-Piñeiro, L | 2 |
| Fiter, L | 2 |
| Mosteiro, JA | 2 |
| Navarro, J | 2 |
| García Matres, MJ | 2 |
| Cárcamo, P | 2 |
| Vera-Donoso, CD | 1 |
| Llopis, B | 4 |
| Oliver, F | 1 |
| Gallego, J | 4 |
| Ruiz, J | 1 |
| Vidal, J | 1 |
| Jiménez Cruz, JF | 1 |
| Saarinen, UM | 1 |
| Pihko, H | 1 |
| Mäkipernaa, A | 1 |
| Wallerstein, R | 1 |
| Spitzer, G | 1 |
| Dunphy, F | 1 |
| Huan, S | 1 |
| Hortobagyi, G | 1 |
| Yau, J | 1 |
| Buzdar, A | 1 |
| Holmes, F | 1 |
| Theriault, R | 1 |
| Ewer, M | 1 |
| Cohen, BE | 1 |
| Egorin, MJ | 1 |
| Kohlhepp, EA | 1 |
| Gutierrez, PL | 1 |
| Russell, KJ | 1 |
| Koh, WJ | 1 |
| Russell, AH | 1 |
| Griffin, BR | 1 |
| Markette, KL | 1 |
| Tong, DY | 1 |
| Griffin, TW | 1 |
| Parmar, MK | 1 |
| Freedman, LS | 1 |
| Hargreave, TB | 1 |
| Tolley, DA | 1 |
| Jordan, AM | 1 |
| Murphy, WM | 1 |
| Fisher, HA | 1 |
| Skeel, RT | 1 |
| Andersen, JW | 1 |
| Benson, AB | 1 |
| Asbury, RF | 1 |
| Pan, JS | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Greco, WR | 1 |
| Gaeta, JF | 1 |
| Huben, RP | 1 |
| Mobley, WC | 1 |
| Loening, SA | 1 |
| Narayana, AS | 1 |
| Culp, DA | 1 |
| Flanigan, RC | 1 |
| Ellison, MF | 1 |
| Butler, KM | 1 |
| Gomella, LG | 1 |
| McRoberts, JW | 1 |
| Mompó, JA | 2 |
| Boronat, F | 3 |
| Alonso, M | 2 |
| Moreno, B | 2 |
| Jiménez, JF | 3 |
| Lancina Martín, J | 1 |
| Monsalve Rodríguez, M | 1 |
| Gómez Cisneros, S | 1 |
| García Alonso, J | 1 |
| Zhang, SX | 1 |
| Deng, XZ | 1 |
| Tang, XD | 1 |
| Levin, DR | 1 |
| Moskovitz, B | 1 |
| Mazeman, E | 1 |
| Rigot, JM | 1 |
| Cracco, D | 1 |
| Sauvage, L | 1 |
| Sánchez, A | 1 |
| Martínez, R | 1 |
| Vera, CD | 1 |
| Yoshida, K | 1 |
| Yamada, K | 1 |
| Aoyama, H | 1 |
| Hashimoto, M | 1 |
| Alter, AJ | 1 |
| Malek, GH | 1 |
| Gilloz, A | 1 |
| Sauvage, I | 1 |
| Gremillet, E | 1 |
| Héritier, P | 1 |
| Richard, A | 1 |
| el Hajj, E | 1 |
| Diez-Yanguas, J | 1 |
| Novak, R | 1 |
| Kern, J | 1 |
| Fister, H | 1 |
| Trnski, D | 1 |
| Dimanovski, J | 1 |
| Kraus, O | 1 |
| Serra, JM | 1 |
| Muirragui, A | 1 |
| Tadjalli, H | 1 |
| Korman, DB | 1 |
| Borisov, AI | 1 |
| Maslova, IA | 1 |
| Pines, EV | 1 |
| Heney, NM | 1 |
| Kluskens, L | 1 |
| Hazra, TA | 1 |
| Trump, DL | 1 |
| Barton, B | 1 |
| Haas, JA | 1 |
| Benson, RC | 1 |
| Hilton, JF | 1 |
| Richard, JM | 1 |
| Sancho, H | 1 |
| Griffen, WO | 1 |
| Humphrey, L | 1 |
| Sosin, H | 1 |
| Sokolova, VD | 1 |
| Sharoukhova, KS | 1 |
| Goncharova, MG | 1 |
| Murav'eva, NI | 1 |
| Smirnova, KD | 1 |
| Schellhammer, PF | 1 |
| Rutishauser, G | 1 |
| Klein, U | 1 |
| Tuchschmid, D | 1 |
| Luzuy, R | 1 |
| Bouzakoura, C | 1 |
| Lunglmayr, G | 2 |
| Czech, K | 1 |
| Zekert, F | 1 |
| Kellner, G | 1 |
| Kierfeld, G | 1 |
| Mellin, P | 1 |
| Veenema, RJ | 2 |
| Romas, NA | 1 |
| Fingerhut, B | 1 |
| Donegan, WL | 2 |
| Wise, L | 1 |
| Corrado, F | 1 |
| Lalanne, G | 1 |
| Pizza, GC | 1 |
| Caramia, G | 2 |
| Rizzo, FP | 2 |
| Rybalka, AN | 1 |
| Mardakhiashvili, ShI | 1 |
| Furnari, S | 1 |
| Veroux, G | 1 |
| Mattea, E | 1 |
| Garin, AM | 1 |
| Karev, NI | 1 |
| Bazhenova, AP | 1 |
| Blokhina, NG | 1 |
| Balas, AN | 1 |
| Rausa, L | 1 |
| Gebbia, N | 1 |
| Arena, E | 1 |
| Tessitore, V | 1 |
| Vecchioni, M | 1 |
| Deutsch, M | 1 |
| Parsons, JA | 1 |
| Atkins, H | 1 |
| Hayward, JL | 1 |
| Klugman, DJ | 1 |
| Wayte, AB | 1 |
| Golomb, FM | 1 |
| Hill, GJ | 1 |
| Larsen, RR | 1 |
| Humphrey, LJ | 1 |
| Jewell, WR | 1 |
| Watne, AL | 1 |
| Covey, TH | 1 |
| Zingg, E | 1 |
| Sulmoni, A | 1 |
| Oravisto, KJ | 1 |
| Spitalier, JM | 1 |
| Amalric, R | 1 |
| Ayme, Y | 1 |
| Desgeorge, Y | 1 |
| Pollet, JF | 1 |
| Fish, J | 1 |
| Smith, EB | 1 |
| Canby, JP | 1 |
| Wescott, JW | 1 |
| Decker, DG | 1 |
| Malkasian, GD | 1 |
| Mussey, E | 1 |
| Johnson, CE | 1 |
| Smith, JP | 1 |
| Rutledge, F | 1 |
| Burns, BC | 1 |
| Soffar, S | 1 |
| Holden, WD | 1 |
| Dixon, WJ | 1 |
| Kuzma, JW | 1 |
| Ansfield, FJ | 1 |
| Watkins, WE | 1 |
| Kozak, JA | 1 |
| Flanagan, MJ | 1 |
| Reuter, JH | 1 |
| Denk, W | 1 |
| Vishniakova, EG | 1 |
| Drew, JE | 1 |
| Marshall, VF | 1 |
| Fisher, B | 4 |
| Ravdin, RG | 3 |
| Ausman, RK | 1 |
| Slack, NH | 4 |
| Moore, GE | 1 |
| Noer, RJ | 1 |
| Hall, TC | 1 |
| Cohn, I | 1 |
| Dean, AL | 1 |
| Uson, AC | 1 |
| Roberts, M | 1 |
| Longo, F | 1 |
| Long, RT | 1 |
| Evans, AM | 1 |
| Getzen, LC | 1 |
| Leipe, ER | 1 |
| Utsunomia, J | 1 |
| Hishiki, S | 1 |
| Nakamura, T | 1 |
| Reilly, MM | 1 |
| Fitzpatrick, PJ | 1 |
| Blumenson, LE | 1 |
| Bross, ID | 1 |
| Moore, FT | 1 |
| Andrews, NC | 1 |
| Cavanaugh, PJ | 1 |
| Gardner, B | 2 |
| Lewison, EF | 1 |
| Dao, TL | 1 |
| State, D | 1 |
| Riddle, PR | 1 |
| Wallace, DM | 1 |
| Mitchell, RJ | 1 |
| Smirnova, IN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer[NCT02716961] | 208 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors[NCT02653196] | Early Phase 1 | 1 participants (Actual) | Interventional | 2015-09-30 | Terminated (stopped due to The Principal Investigator left the institution.) | ||
| A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors.[NCT00851110] | Phase 2 | 50 participants (Anticipated) | Interventional | 2004-10-31 | Terminated | ||
| High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up of a Randomized Phase III Study[NCT03087409] | 885 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme[NCT00088400] | Phase 3 | 30 participants | Interventional | 2004-07-31 | Completed | ||
| Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471] | Phase 2 | 44 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco[NCT00003081] | Phase 1 | 16 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma[NCT03664869] | Phase 3 | 300 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study[NCT03597087] | 289 participants (Anticipated) | Interventional | 2018-07-19 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
24 reviews available for thiotepa and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma.
Topics: Central Nervous System Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Tran | 2014 |
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2016 |
Bladder cancer: current optimal intravesical treatment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystectomy | 2005 |
Intravesical chemotherapy of superficial bladder cancer.
Topics: Absorption; Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Endoscopy; | 1983 |
The biology and treatment of superficial bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Squamous Cell; Carcinoma, Trans | 1984 |
Intravesical chemotherapy in the management of superficial bladder tumors.
Topics: Antineoplastic Agents; BCG Vaccine; Doxorubicin; Humans; Mitomycins; Neoplasm Recurrence, Local; Thi | 1984 |
Rationale for intensive intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Humans; Mitomycins; Neoplasm Recurrence, Local; Thiotepa; Urinar | 1984 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
Intravesical and systemic chemotherapy in the management of superficial bladder cancer.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Cisplati | 1984 |
Rationale for intensive intravesical chemotherapy for superficial bladder cancer.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Doxorubicin; Humans; Mito | 1980 |
Treatment of superficial bladder cancer.
Topics: Aged; Antineoplastic Agents; BCG Vaccine; Cystoscopy; Humans; Immunotherapy; Male; Methods; Neoplasm | 1980 |
[Progress in the internist treatment of bladder tumors].
Topics: Antineoplastic Agents; BCG Vaccine; Cisplatin; Doxorubicin; Ethoglucid; Humans; Leucovorin; Methotre | 1982 |
[Treatment strategy to obtain cure for recurrent advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carbo | 1994 |
BCG in perspective: advances in the treatment of superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Doxorubicin; Humans; Mitomycin; Neoplasm Recurrence, Loca | 1995 |
[High-dose chemotherapy in relapse of medulloblastoma in young children].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cerebellar Ne | 1997 |
Optimal BCG treatment of superficial bladder cancer as defined by American trials.
Topics: Administration, Intravesical; Administration, Oral; BCG Vaccine; Carcinoma in Situ; Carcinoma, Trans | 1992 |
Graft versus host disease prophylaxis today.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Bone Marrow Transplantation; Cyclophosphamide | 1991 |
Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1989 |
BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Topics: Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Mal | 1989 |
Intravesical therapy for bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystoscopy; Doxorubicin; Female; H | 1988 |
The prognosis and management of recurrent abdominal malignancies.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Ca | 1969 |
Chemotherapy for bladder cancer.
Topics: Administration, Topical; Alkylating Agents; Blood Cell Count; Carcinoma, Papillary; Cystitis; Cystos | 1974 |
Controversies in the management of potentially curable breast cancer.
Topics: Breast Neoplasms; Castration; Clinical Trials as Topic; England; Female; Fluorouracil; Humans; Lymph | 1974 |
Chemotherapy of breast cancer.
Topics: Adrenal Cortex Hormones; Alkaloids; Alkylating Agents; Androgens; Antimetabolites; Antineoplastic Ag | 1968 |
73 trials available for thiotepa and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Rec | 2022 |
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Prote | 2020 |
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2016 |
Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neop | 2010 |
High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms | 2010 |
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2003 |
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2003 |
High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebel | 2005 |
Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cent | 2006 |
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Topics: Adult; Anthracyclines; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarker | 2006 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Doxorubicin; Female; Humans; Male; Middl | 1983 |
Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).
Topics: Aged; Antineoplastic Agents; Carcinoma; Cell Differentiation; Cisplatin; Clinical Trials as Topic; D | 1983 |
Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group.
Topics: Humans; Neoplasm Recurrence, Local; Prognosis; Teniposide; Thiotepa; Urinary Bladder Neoplasms | 1983 |
Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa.
Topics: Aged; Carcinoma, Transitional Cell; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Lo | 1983 |
Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Ci | 1983 |
Cooperative studies of chemoprophylaxis after transurethral resection of bladder tumors.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Cisplatin; Clinical Trials as Topic; Combined Modality | 1983 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
Intravesical treatment with thiotepa: an update review.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Neoplasm | 1984 |
Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cisplatin; Clini | 1984 |
Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Follow-Up Studies; Humans; Neoplasm Recurren | 1982 |
Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Topics: BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Neo | 1982 |
Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1995 |
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 1995 |
The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working P
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cystoscopy; Drug | 1994 |
Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Glioma; Humans; Male; Middle Ag | 1993 |
Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide | 1993 |
Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1993 |
A phase II evaluation of thiotepa in pediatric central nervous system malignancies.
Topics: Adolescent; Adult; Brain Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Drug Administrati | 1993 |
ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour.
Topics: Absorption; Administration, Intravesical; Aged; Analysis of Variance; Antineoplastic Agents, Alkylat | 1996 |
Contemporary chemotherapy issues for children with brainstem gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carboplatin; Carmustine; Dose-Response Relations | 1996 |
A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neopl | 1996 |
Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Etoposide; | 1997 |
Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carbop | 1998 |
A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Infusions, P | 1998 |
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1999 |
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinom | 2001 |
[Prevention of postoperative recurrence of bladder cancer: a clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; BCG | 1999 |
Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study.
Topics: Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Pathology; Podophyllotoxin; Random Allocation; | 1978 |
The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A.
Topics: Clinical Trials as Topic; Humans; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Postopera | 1977 |
Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer.
Topics: Administration, Oral; Administration, Topical; Clinical Trials as Topic; Drug Evaluation; Follow-Up | 1977 |
Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Electrocoagulation; Female; Follow-Up Studie | 1976 |
EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma.
Topics: Carcinoma, Papillary; Clinical Trials as Topic; Follow-Up Studies; Humans; Neoplasm Recurrence, Loca | 1976 |
[Neoadjuvant chemotherapy in combined treatment of breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1992 |
A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.
Topics: Administration, Intravesical; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Proto | 1992 |
Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1992 |
[BCG in superficial carcinoma of the bladder. Authors' experience].
Topics: Administration, Topical; Adult; Aged; BCG Vaccine; Carcinoma in Situ; Drug Evaluation; Female; Human | 1992 |
Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Or
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 1992 |
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Pro | 1991 |
Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional C | 1990 |
Selective chemoprophylaxis guided by multifactorial analysis in superficial bladder cancer.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; | 1990 |
Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Cystoscopy; Follow-Up Studies; Humans; M | 1989 |
Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional C | 1989 |
BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Topics: Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Mal | 1989 |
The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystoscopy; Humans; Middle Aged | 1985 |
A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Humans; Mitomycin; Mitomycins; Neoplasm Recu | 1986 |
Crossed chemoprophylaxis assay between adriamycin and cis-platinum in recurrent superficial bladder tumor.
Topics: Cisplatin; Doxorubicin; Humans; Neoplasm Recurrence, Local; Random Allocation; Thiotepa; Urinary Bla | 1986 |
Prophylactic treatment for superficial bladder cancer following transurethral resection.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Combined Mo | 1987 |
[Evaluation of regimens for the simultaneous and sequential administration of cytostatics in the combined chemotherapy of disseminated forms of breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1985 |
Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
Topics: Administration, Topical; Biopsy; Carcinoma in Situ; Clinical Trials as Topic; Cystitis; Cystoscopy; | 1985 |
Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1985 |
Extended surgical adjuvant thiotepa for mammary carcinoma.
Topics: Adenocarcinoma; Blood Cell Count; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Femal | 1974 |
Controversies in the management of potentially curable breast cancer.
Topics: Breast Neoplasms; Castration; Clinical Trials as Topic; England; Female; Fluorouracil; Humans; Lymph | 1974 |
Treatment of early breast cancer: a report after ten years of a clinical trial.
Topics: Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Lymphatic | 1972 |
The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of colorectal carcinoma.
Topics: Adult; Aged; Black or African American; Colonic Neoplasms; Ethnology; Female; Humans; Injections, In | 1967 |
Chemotherapy in primary therapy of cancer of the breast.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mast | 1967 |
Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.
Topics: Adult; Aged; Axilla; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouraci | 1968 |
Complications and toxic manifestations of surgical adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Blood Cell Count; Blood Platelets; Blood Transfusion; Breast Neoplasms; Clinical Trials | 1968 |
Extended surgical adjuvant chemotherapy for breast carcinoma.
Topics: Adenocarcinoma; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lymphatic Metastasis; Ma | 1969 |
Postoperative radiotherapy in the treatment of breast cancer: results of the NSABP clinical trial.
Topics: Adult; Age Factors; Breast Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Maste | 1970 |
Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma.
Topics: Adult; Breast Neoplasms; Castration; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Ma | 1970 |
162 other studies available for thiotepa and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra | 2022 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Topics: Adult; Central Nervous System; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Human | 2023 |
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Central Nervous Syste | 2023 |
How I treat secondary CNS involvement by aggressive lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lym | 2023 |
Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic A | 2019 |
Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.
Topics: Antilymphocyte Serum; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic | 2020 |
Tandem High-dose Chemotherapy without Craniospinal Irradiation in Treatment of Non-metastatic Malignant Brain Tumors in Very Young Children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child, Preschool; Cran | 2020 |
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cohort Studies; Cyclop | 2021 |
Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System; Combi | 2021 |
Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; CD8-Positive T | 2019 |
Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous Syst | 2013 |
Case-cohort analysis of clusters of recurrent events.
Topics: Cluster Analysis; Cohort Studies; Computer Simulation; Humans; Likelihood Functions; Neoplasm Recurr | 2014 |
Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2015 |
Whither thiotepa (for patients in the USA)?
Topics: Antineoplastic Agents, Alkylating; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Th | 2015 |
Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplas | 2015 |
Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2017 |
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transpla | 2008 |
No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms; Child | 2009 |
Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nerv | 2009 |
High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2009 |
Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2011 |
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combin | 2011 |
[Sustained complete remission of intravascular large B-cell lymphoma with recurrent CNS involvement by autologous peripheral blood stem cell transplantation preconditioned with TBC regimen].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2011 |
Weighted logrank tests for interval censored data when assessment times depend on treatment.
Topics: Antineoplastic Agents, Alkylating; Bias; Biometry; Cluster Analysis; Computer Simulation; Data Inter | 2012 |
Successful treatment of a recurrent choroid plexus carcinoma with surgery followed by high-dose chemotherapy and stem cell rescue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carcinoma; Choroid Plexus Neoplasms; Combi | 2013 |
[Triethylene-phosphoramide or thio-TEPA in therapy of recurrent cancer of the breast].
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasms; Phos | 1959 |
ADJUVANT CHEMOTHERAPY (TRIETHYLENE THIOPHOSPHORAMIDE) WITH RADICAL MASTECTOMY AND RADIOTHERAPY IN BREAST CANCER.
Topics: Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Humans; Leukopenia; Mastectomy; Mastectomy, Rad | 1963 |
[PREVENTION OF THE RECURRENCE OF CANCER].
Topics: Animals; Biomedical Research; Genetic Diseases, X-Linked; Hormones; Leukemia, Hairy Cell; Lymphatic | 1964 |
CYCLOPHOSPHAMIDE IN TREATMENT OF LOCALLY RECURRENT BREAST CANCER.
Topics: Androgens; Breast; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Estrogens; Humans; Hypophysecto | 1965 |
DISSEMINATION OF CANCER WITH SPECIAL EMPHASIS ON VASCULAR SPREAD AND IMPLANTATION.
Topics: Geriatrics; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplasms; Ne | 1965 |
High-dose thiotepa and etoposide in children with poor-prognosis brain tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplati | 2004 |
Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dise | 2004 |
Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cy | 2004 |
High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophos | 2004 |
Multifocal motor neuropathy with conduction block associated with metastatic lymphoma of the nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Demyelinating Diseases; Female; He | 2006 |
A case of relapsing glioblastoma multiforme responding to vinorelbine.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Combin | 2006 |
[A case of recurrent breast cancer complicated with pericardial effusions and cardiac tamponade].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 2006 |
Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschoo | 2007 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain | 2008 |
High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Busulfan; Cerebellar Neoplasms; Child | 2007 |
[A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 2007 |
Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant | 2008 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2008 |
Minimal breast cancer. Clinical characteristics and treatment results.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Female; H | 1983 |
A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; BCG Vaccine; Carcinoma, Transitional Cel | 1983 |
Bladder cancer. Management of an increasingly common tumor.
Topics: Endoscopy; Humans; Neoplasm Recurrence, Local; Thiotepa; Urinary Bladder Neoplasms | 1983 |
[Use of thiotepa, in local instillation, as a prophylactic treatment for recurrence of superficial tumors of the bladder].
Topics: Administration, Topical; Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Age | 1983 |
Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study.
Topics: Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Invasiv | 1983 |
The influence of lower urinary tract infection on the recurrence rate of superficial transitional cell carcinoma of the bladder.
Topics: Aged; Animals; Anti-Bacterial Agents; Carcinoma, Transitional Cell; Cystitis; Dogs; Female; Humans; | 1983 |
Does intravesical chemotherapy prevent invasive bladder cancer?
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Follow-Up Studie | 1984 |
Intrapelvic thiotepa for re-recurrence of transitional cell carcinoma of the renal pelvis in a solitary kidney.
Topics: Carcinoma, Transitional Cell; Female; Humans; Kidney Neoplasms; Kidney Pelvis; Middle Aged; Neoplasm | 1984 |
[The effect of various factors on the results of chemotherapy in patients with recurrent ovarian serous cystadenocarcinoma].
Topics: Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma; Female; Huma | 1984 |
Bilateral primary carcinoma of the ureter: topical intraureteral thiotepa.
Topics: Administration, Topical; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; Neoplasm Recurrenc | 1984 |
Management of superficial bladder carcinoma with BCG. Long term follow-up.
Topics: BCG Vaccine; Combined Modality Therapy; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Thiot | 1984 |
The value of thiotepa in the treatment of superficial bladder tumors.
Topics: Adult; Aged; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neopla | 1984 |
The effects of intravesical instillation of Thio-Tepa on the recurrence rate of bladder tumors.
Topics: Adolescent; Adult; Aged; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Thiotepa | 1980 |
Conservative management of low grade neoplasms of the male urethra: a preliminary report.
Topics: Adult; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Middle Ag | 1980 |
The management of superficial bladder cancer.
Topics: Adenocarcinoma; Carcinoma, Papillary; Carcinoma, Transitional Cell; Humans; Methods; Mitomycins; Neo | 1980 |
[Use of a combination of pyrogenal and drug preparations in the overall treatment of breast cancer].
Topics: Adult; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; M | 1980 |
[The recurrence after conservative therapy of bladder cancer. II: The intravesical instillation of anti-cancer drug for preventing recurrence (author's transl)].
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Child; Female; Humans; Male; Midd | 1980 |
The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder.
Topics: Humans; Neoplasm Recurrence, Local; Remission, Spontaneous; Thiotepa; Urinary Bladder; Urinary Bladd | 1981 |
[Reoperation for severe hematuria following chemotherapy for bladder papillomatosis previously treated by surgery and cobalt therapy].
Topics: Administration, Topical; Aged; Hematuria; Humans; Male; Neoplasm Recurrence, Local; Papilloma; Thiot | 1981 |
[Effect of cytostatics on tumor cells].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Female; Humans; Lung Neoplasms; Male; Mesothelioma; | 1980 |
Intravesical thiotepa in prevention of recurrence of bladder tumour.
Topics: Adult; Female; Humans; Male; Neoplasm Recurrence, Local; Thiotepa; Urinary Bladder; Urinary Bladder | 1980 |
[Combination chemotherapy including anablastine in disseminated breast cancer].
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; | 1981 |
Use of intravesical thiotepa in superficial bladder tumours.
Topics: Administration, Topical; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neopla | 1981 |
Early multiple-dose adjuvant thiotepa in the control of multiple and rapid T1 tumour neogenesis.
Topics: Drug Administration Schedule; Electrocoagulation; Female; Humans; Male; Middle Aged; Neoplasm Recurr | 1981 |
[Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Dru | 1981 |
Intravitreal chemotherapy for recurrent retinoblastoma in an only eye.
Topics: Combined Modality Therapy; Eye Neoplasms; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; | 1995 |
Regional chemotherapy for melanoma. A 35-year experience.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials as Topic; Combined Modality T | 1994 |
TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1994 |
Rapid tumour recurrence following cessation of long-term treatment with intravesical thiotepa.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional Cell; Fe | 1994 |
[Tumors of the superior urinary tract and associated bladder tumors: clinical and etiological aspects].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Cystectomy; Female; Follow-Up Studies; Humans; I | 1993 |
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brai | 1996 |
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brai | 1996 |
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brai | 1996 |
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brai | 1996 |
Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea | 1996 |
Pediatric leptomeningeal metastases: outcome following combined therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebrospinal Fluid; Chemotherapy, Cance | 1997 |
Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs other than L-phenylalanine mustard.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemotherapy, Cancer, Regional P | 1997 |
[High-dosage chemotherapy and autologous transplant of hematopoietic germ cells from peripheral blood in high-risk recurrence carcinoma of the breast (with >= or 10 involved axillary nodes at diagnosis) Preliminary results of the Solti 9301 cooperative st
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Combin | 1997 |
High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms | 1998 |
[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami | 1997 |
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 2000 |
A general family of distributions for longitudinal dependence with special reference to event histories.
Topics: Antineoplastic Agents, Alkylating; Granulomatous Disease, Chronic; Humans; Interferon-gamma; Longitu | 2001 |
[Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Duc | 1999 |
High-dose adjuvant chemotherapy for patients with high-risk breast cancer: efficacy is still an open question.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvan | 2000 |
Intrathecal thiotepa: reappraisal of an established therapy.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Cerebrospinal Fluid; Child; Child, Preschool; Cohort | 2002 |
Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Ph | 2002 |
Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder.
Topics: Adolescent; Adult; Aged; Animals; Carcinoma, Transitional Cell; Child; Child, Preschool; Dogs; Follo | 1978 |
Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Bacterial Vaccines; BCG Vaccine; Dacarbazine; Drug | 1978 |
Local application of THIO-TEPA in the prevention of recurrent papillary carcinoma of the bladder.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Papillary; Female; Humans; Male; Middle Aged; Neopl | 1979 |
Intravesical chemotherapy and chemoprevention of superficial, low grade, low stage bladder carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Neoplasm Recurrence, Local; Thiotepa; T | 1979 |
[Chemotherapy of bladder neoplasms--studies of preventive measures against recurrence of superficial bladder neoplasms].
Topics: Carcinoma, Transitional Cell; Female; Humans; Male; Mitomycins; Neoplasm Recurrence, Local; Thiotepa | 1977 |
[Endoscopic resection in the treatment of non-invasive excreto-urinary carcinomas of the bladder 146 endoscopic resections carried out in 53 patients].
Topics: Adult; Aged; Animals; Carcinoma, Papillary; Endoscopy; Female; Humans; Male; Middle Aged; Neoplasm R | 1977 |
Proceedings: Adjuvant intravesical thiotepa and bladder tumour recurrence.
Topics: Humans; Neoplasm Recurrence, Local; Neoplasm Seeding; Thiotepa; Urinary Bladder Neoplasms | 1975 |
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
Topics: Adolescent; Adult; Aged; Carcinoma, Transitional Cell; Cystitis; Drug Therapy, Combination; Endopept | 1975 |
Survival after regional perfusion for limb melanoma.
Topics: Amputation, Surgical; Chemotherapy, Cancer, Regional Perfusion; Extremities; Female; Humans; Lymphat | 1975 |
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Topics: Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Hypersensitivity, Delayed; Immunoth | 1976 |
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Topics: Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Hypersensitivity, Delayed; Immunoth | 1976 |
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Topics: Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Hypersensitivity, Delayed; Immunoth | 1976 |
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Topics: Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Hypersensitivity, Delayed; Immunoth | 1976 |
[Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 1992 |
Recurrence and treatment of urinary bladder cancer after failure in radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Doxorubicin; Female; Humans; Male; Middle | 1990 |
[Superficial bladder cancer: prophylaxis of recurrence and progression].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Bleomycin; Cisplatin; Doxorubicin; | 1991 |
Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1991 |
High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: a case report.
Topics: Bone Marrow Transplantation; Brain Neoplasms; Child; Combined Modality Therapy; Dose-Response Relati | 1990 |
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea | 1990 |
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, Gas; | 1986 |
Combined intracavitary and external beam irradiation for superficial transitional cell carcinoma of the bladder: an alternative to cystectomy for patients with recurrence after intravesical chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Transitional Cell; C | 1989 |
Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1989 |
Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder.
Topics: Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Cautery; Disease Models, Animal | 1989 |
Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Topics: Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; Cisplatin; Cystoscopy; Drug Evaluation; Dru | 1986 |
[Chemoprophylaxis with intravesical thiotepa in non-infiltrating bladder tumors].
Topics: Administration, Intravesical; Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, L | 1986 |
[Intravesical application of thio-tepa for preventing postoperative recurrence of bladder carcinoma].
Topics: Administration, Intravesical; Carcinoma, Squamous Cell; Humans; Neoplasm Recurrence, Local; Postoper | 1986 |
Distilled water versus chemotherapeutic agents for transitional bladder carcinoma.
Topics: Carcinoma, Transitional Cell; Cell Survival; Humans; In Vitro Techniques; Mitomycin; Mitomycins; Neo | 1986 |
[Vesicorenal reflux following endoscopic treatment of vesical tumors. Developmental and therapeutic complications].
Topics: Aged; Carcinoma, Papillary; Cystoscopy; Humans; Kidney Diseases; Male; Middle Aged; Neoplasm Recurre | 1986 |
[Prognostic factors and risk of recurrence in a series of 385 patients with superficial bladder carcinoma treated with thiotepa, adriamycin or cisplatin].
Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Female; Humans; Male; Neoplasm Recurrence, Local; Pro | 1987 |
Bladder wall calcification after topical mitomycin C.
Topics: Administration, Intravesical; Aged; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Ther | 1987 |
[Preventive value of intravesical thiotepa on the recurrence of Ta-T1 vesical tumors treated by conservative surgery. Apropos of 247 cases a mean follow-up of 88 months].
Topics: Administration, Intravesical; Combined Modality Therapy; Follow-Up Studies; Humans; Neoplasm Recurre | 1987 |
Effects of local chemotherapy and immunotherapy on the recurrence and progression of superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; | 1988 |
Extensive distal subcutaneous metastases of a "benign" giant cell tumor of the radius.
Topics: Adult; Bone Neoplasms; Doxorubicin; Female; Giant Cell Tumors; Hand; Humans; Neoplasm Metastasis; Ne | 1985 |
Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors.
Topics: Cisplatin; Doxorubicin; Drug Evaluation; Humans; Neoplasm Recurrence, Local; Postoperative Care; Thi | 1985 |
Management of superficial bladder cancer in a community setting.
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Transitional Cell; Cost-Benefit Analysis; Geo | 1985 |
[Intra-arterial chemotherapy of head and neck tumors: statistical study of 129 cases treated at the Institut Gustave Roussy].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Facial Neoplasms | 1973 |
[FSH and steroid hormone excretion in breast cancer during chemotherapy].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Breast Neoplasms; Cyclophosphamide; Estrogens; Female; F | 1972 |
Renal failure associated with the use of thio-tepa.
Topics: Acute Kidney Injury; Aged; Autopsy; Carcinoma, Transitional Cell; Humans; Inflammation; Male; Neopla | 1973 |
[The so-called benign tumors of the urinary tract].
Topics: Adult; Female; Hematuria; Humans; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Papilloma; Thi | 1973 |
[Benign bladder papillomas, prognosis and treatment. Attempt at an anatomo-clinical correlation].
Topics: Aged; Female; Humans; Male; Neoplasm Recurrence, Local; Papilloma; Prognosis; Thiotepa; Urinary Blad | 1973 |
Bladder hyperthermia in the treatment of vesical papillomatosis.
Topics: Bacitracin; Buffers; Drug Combinations; Follow-Up Studies; Hematuria; Hot Temperature; Humans; Leuko | 1973 |
[Thio-tepa in the prevention of recurrences of papillary bladder tumors].
Topics: Aged; Blood Cell Count; Blood Platelets; Carcinoma, Papillary; Female; Follow-Up Studies; Humans; Le | 1973 |
Chemoprophylaxis of bladder cancer recurrence: immunological aspects.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Humans; Immune Adherenc | 1974 |
[Local chemotherapy in vesical neoplasms].
Topics: Antineoplastic Agents; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Neoplasm Recurr | 1974 |
[Repeat surgery for recurring thecoma of the ovary].
Topics: Androgens; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Thecoma; Thio | 1967 |
[On the prevention of postoperative recurrences in cancer of the ovaries].
Topics: Adult; Cyclophosphamide; Cystadenoma; Dysgerminoma; Female; Granulosa Cell Tumor; Humans; Middle Age | 1968 |
Cancer chemotherapy in urology.
Topics: Adenocarcinoma; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Chlorambucil; Cobal | 1971 |
[Results of a comparative study of the efficacy of treatment of early forms of breast neoplasms by different methods].
Topics: Adenocarcinoma, Scirrhous; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Neoplasm Metast | 1973 |
Clinical and experimental projects on chemotherapy of bladder tumours.
Topics: Absorption; Alkylating Agents; Animals; Antineoplastic Agents; Cricetinae; Dogs; Drug Therapy, Combi | 1974 |
Thio-TEPA and supervoltage radiotherapy for carcinoma of the ovary.
Topics: Adenocarcinoma, Papillary; Carcinoma; Cystadenocarcinoma; Cystadenoma; Evaluation Studies as Topic; | 1972 |
[Cytostatic prophylactic treatment of superficial bladder tumours].
Topics: Adult; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Papilloma; Thiotepa; Time Factors; Uri | 1972 |
Perfusion of melanoma. 105 isolated perfusions in 92 patients.
Topics: Chemotherapy, Cancer, Regional Perfusion; Dactinomycin; Humans; Melanoma; Melphalan; Neoplasm Recurr | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Chemotherapy for recurrent carcinoma of the breast.
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Hepatic Artery; Humans; Injections, | 1972 |
Hormones, chemotherapy, and the breast cancer patient.
Topics: Administration, Oral; Adrenalectomy; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Female; Fluoro | 1972 |
Chemotherapy in superficial neoplasms of the bladder.
Topics: Acids; Carcinoma, Papillary; Humans; Neoplasm Recurrence, Local; Papilloma; Precancerous Conditions; | 1972 |
Optimal intravesical dosage of thio-tepa in the prophylaxis of recurrent bladder papillomatosis.
Topics: Administration, Oral; Cystoscopy; Humans; Injections; Leukopenia; Neoplasm Recurrence, Local; Papill | 1972 |
[Thio-tepa in recurring carcinomas of the cervix uteri. Results].
Topics: Female; Humans; Neoplasm Recurrence, Local; Thiotepa; Uterine Cervical Neoplasms | 1966 |
Malignant melanoma in childhood.
Topics: Humans; Infant; Lymph Node Excision; Male; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local | 1966 |
The prophylactic use of thio-TEPA in transitional cell carcinoma of the bladder.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, L | 1966 |
Cyclophosphamide. Evaluation in recurrent and progressive ovarian cancer.
Topics: Cyclophosphamide; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ova | 1967 |
Systemic chemotherapy for carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fema | 1967 |
Severe pancytopenia associated with the use of intravesical thio-TEPA.
Topics: Aged; Anemia, Aplastic; Carcinoma, Transitional Cell; Humans; Leukocyte Count; Male; Neoplasm Recurr | 1967 |
[New experience with cytostatics, especially their intra-arterial use in bladder tumors].
Topics: Antineoplastic Agents; Electrosurgery; Humans; Injections, Intra-Arterial; Neoplasm Recurrence, Loca | 1966 |
[Follow-up therapy with cytostatic drugs following surgery].
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Bronchogenic; Cyclophosphamide; Female; Humans; Neoplas | 1966 |
[Hormonal prevention of recurrence and metastasis in the complex treatment of breast cancer].
Topics: Adult; Aged; Androgens; Breast Neoplasms; Castration; Estrogens; Female; Humans; Mastectomy; Middle | 1968 |
The effects of topical THIOTEPA on the recurrence rate of superficial bladder cancers.
Topics: Aged; Female; Humans; Male; Middle Aged; Mucous Membrane; Neoplasm Recurrence, Local; Thiotepa; Urin | 1968 |
Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors.
Topics: Blood Platelet Disorders; Cystitis; Cystoscopy; Humans; Leukopenia; Neoplasm Recurrence, Local; Solu | 1969 |
The treatment of primary breast cancer. Comments.
Topics: Adrenalectomy; Breast Neoplasms; Castration; Female; Humans; Hypophysectomy; Lymphatic Metastasis; N | 1969 |
[Results of the surgical treatment of lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Follow-Up Studies; | 1969 |
[Surgical adjuvant chemotherapy of stomach cancer, with special reference to follow-up study of thio-TEPA and future problems].
Topics: Female; Follow-Up Studies; Humans; Male; Mitomycins; Neoplasm Recurrence, Local; Sex Factors; Stomac | 1969 |
Adjuvant chemotherapy in primary treatment of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Humans; Mastectomy; Mechlorethami | 1969 |
Therapeutic implications from a mathematical model characterizing the course of breast cancer.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mastectomy; | 1969 |
Prospects for the control of metastases.
Topics: Anticoagulants; Breast Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Recur | 1969 |
Evaluation of adjunctive chemotherapy for recurrent cancer.
Topics: Animals; Breast Neoplasms; Female; Fluorouracil; Humans; Mice; Neoplasm Recurrence, Local; Neoplasms | 1970 |
Intracavitary chemotherapy for multiple non-invasive bladder tumours.
Topics: Alkylating Agents; Carcinoma, Papillary; Humans; Leukopenia; Neoplasm Recurrence, Local; Thiotepa; U | 1971 |
Intravesical thiotepa in the treatment of transitional cell bladder carcinoma.
Topics: Aged; Bone Marrow; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Neoplasm Recurre | 1971 |
[Results of treatment of tonsillar tumors by olivomycin].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Chlorpromazine; Cyclophosp | 1969 |